CORRELATIVE STUDY OF RADIORECEPTOR ASSAY AND RADIOIMMUNOASSAY OF SERUM GROWTH HORMONE IN CHILDREN: NORMAL CHILDREN AND HGH -TREATED PITUITARY DWARFS

1977 ◽  
Vol 86 (1) ◽  
pp. 50-59 ◽  
Author(s):  
Philippe E. Garnier ◽  
Jean-Claude Job ◽  
A. M. Repellin

ABSTRACT A sensitive and reproducible radioreceptor assay (RRA) for human growth hormone (HGH) is described. It allows the evaluation of HGH concentrations as low as 2 ng/ml. It has a limited cross-reactivity with human prolactin, which does not interfere at physiological levels in children. Comparison of the results with those of radioimmunoassay (RIA) showed no discrepancies in the serum of normal children before and after stimulation tests for GH (mean RRA/RIA ratio 1.03 ± sem 0.04, range 0.75 to 1.65) nor in the serum from hypopituitary dwarfs during the 12 h following an im injection of 6 mg of HGH (mean RRA/RIA ratio 1.05 ± sem 0.04, range 0.84 to 1.28). It is concluded that receptoractivity of HGH is parallel to its immunoreactivity in normal children and in hypopituitary patients receiving clinical grade HGH.

2004 ◽  
Vol 2004 (3) ◽  
pp. 143-149 ◽  
Author(s):  
Juliana F. Moura ◽  
Luiz DeLacerda ◽  
Romolo Sandrini ◽  
Fernanda M. Borba ◽  
Denise N. Castelo ◽  
...  

Human growth hormone (hGH) signal transduction initiates with a receptor dimerization in which one molecule binds to the receptor through sites 1 and 2. A sandwich enzyme-linked immunosorbent assay was developed for quantifying hGH molecules that present helix 4 from binding site 1. For this, horse anti-rhGH antibodies were eluted by an immunoaffinity column constituted by sepharose-rhGH. These antibodies were purified through a second column with synthetic peptide correspondent tohGH helix 4, immobilized to sepharose, and used as capture antibodies. Those that did not recognize synthetic peptide were used as a marker antibody. The working range was of 1.95 to 31.25 ng/mL of hGH. The intra-assay coefficient of variation (CV) was between 4.53% and 6.33%, while the interassay CV was between 6.00% and 8.27%. The recovery range was between 96.0% to 103.8%. There was no cross-reactivity with human prolactin. These features show that our assay is an efficient method for the determination of hGH.


1978 ◽  
Vol 88 (2) ◽  
pp. 227-238 ◽  
Author(s):  
Philippe E. Garnier ◽  
A. M. Repellin ◽  
Jean-Claude Job

ABSTRACT Growth hormone (GH) was measured by radioreceptorassay (RRA) and radioimmunoassay (RIA) in the sera of 24 children with idiopathic primary growth retardation (PGR), 15 with genetic short stature (GSS) and 11 with intra-uterine growth retardation (IUGR), and compared to results obtained in normal children. The average RRA/RIA ratio was close to normal in PGR (1.02 ± 0.05) and in IUGR (1.06 ± 0.07), and slightly though not significantly lower in GSS (0.86 ± 0.06). Some variability in RRA/RIA ratio was found in individual patients of each group, and some sera gave a non-parallel displacement of the tracer when compared to the standard curve. But no genetic difference of RRA-assayable GH was found between the three groups studied and normal children.


1977 ◽  
Vol 86 (2) ◽  
pp. 243-250 ◽  
Author(s):  
Y. Okada ◽  
K. Watanabe ◽  
T. Takeuchi ◽  
T. Hata ◽  
H. Mikam ◽  
...  

ABSTRACT A propranolol-glucagon test was evaluated in 24 control normal children, 21 pituitary dwarfs, 15 patients with constitutional short stature, 2 with chromosome aberration and 4 with miscellaneous diseases. The dose of glucagon enough for the stimulation of human growth hormone (HGH) secretion is more than 20 μg/kg of body weight. During the test in the control subjects the serum HGH level increased from 2.3 ± 1.2 ng/ml to a maximum level of 30.0 ± 15.1 ng/ml, when 10 mg propranolol, regardless of body weight and 30 μg glucagon per kg of body weight are given. The dose of propranolol administered ranged from 0.2 to 1.0 mg/kg of body weight in normal children studied. Serum 11-OHCS also increased significantly from 14.5 ± 11.2 μg/100 ml to 30.1 ± 15.5 μg/100 ml (P <0.01). There was no difference in the maximum level of urinary total catecholamines in propranolol-glucagon test between 7 pituitary dwarfs and 7 control subjects. The mechanism of HGH response to propranolol-glucagon administration is unknown, but propranolol-glucagon administration is a sensitive and reliable provocative test for HGH secretion, since false negative responses of HGH are not observed in patients with non-pituitary disease.


PEDIATRICS ◽  
1974 ◽  
Vol 53 (6) ◽  
pp. 929-937
Author(s):  
S. Douglas Frasier

No suggested screening test meets all of the criteria set for such a procedure. The minimum incidence of a positive response in normal children detected in a single blood sample after diethylstilbestrol, sleep or exercise is approximately 70%. This is higher than that observed when a single sample is obtained following oral glucose. While both sleep and exercise are physiologic stimuli, the former may be quite inconvenient unless an outpatient facility staffed with appropriate personnel is available. An exercise test employed in the office may well be the best screening procedure for the practicing physician. The optimal criteria for a definitive test of growth hormone function are also not met by any single stimulus. Insulin-induced hypoglycemia, arginine infusion, intramuscular glucagon and oral 1-DOPA are all useful procedures. None alone discriminate completely between the normal and the growth hormone-deficient child. Despite potential hazards, insulin-induced hypoglycemia remains the standard against which other stimuli are judged. Arginine and 1-DOPA appear to be equally effective. The literature contains insufficient data to allow adequate evaluation of intramuscular glucagon alone, and the results of combined propranolol-glucagon stimulation, while promising, require confirmation. Because of an inconstant and/or small magnitude of response leading to results which are difficult to interpret, the use of glucose, pyrogen, vasopressin and ACTH are not adequate tests of growth hormone function. Bovril® is a satisfactory stimulus for those children who will take it. Those factors which modify the growth hormone response must be considered in evaluating the results of stimulation tests. Blunted responses should be interpreted with extreme caution in the obese child. A fasting growth hormone concentration ≥ 7 ng/ml is presumptive evidence of intact growth hormone function regardless of the subsequent response to stimulation. It is essential that patients be euthyroid in order to interpret the results of growth hormone function tests. Physiologic glucocorticoid replacement therapy should not confuse the interpretation of results. Whether or not pretreatment with sex steroids is worthwhile in the routine evaluation of children for suspected growth hormone deficiency is an open question. Although it is agreed that the definitive diagnosis of growth hormone deficiency depends on the demonstration of failure to respond to two stimuli, which two are most satisfactory is not settled. The sequential administration of arginine and insulin on the same day appears to limit significantly the incidence of false-positive laboratory diagnoses of growth hormone deficiency. The significance of intermediate values in response to stimulation remains unclear. Caution should be exercised in assigning a child to the category of partial growth hormone deficiency. This question must be answered ultimately by the response to HGH therapy in the individual patient. Finally, several points should be kept in mind. All of the tests described depend on the detection and quantitation of immunologically active HGH and biological activity is not necessarily associated with the material(s) being measured. Since many of the stimuli used in the evaluation of growth hormone function are clearly pharmacologic, the physiological significance of the response to such stimuli must be interpreted with caution. The best current evidence suggests that all of the stimuli described act through an intact hypothalamus and pituitary. Differentiation between hypothalamic and pituitary sites of defective growth hormone function awaits the availability of growth hormone-releasing factor(s).


1974 ◽  
Vol 63 (1) ◽  
pp. 21-34 ◽  
Author(s):  
W. M. HUNTER ◽  
F. J. GILLINGHAM ◽  
P. HARRIS ◽  
J. A. KANIS ◽  
F. M. McGURK ◽  
...  

SUMMARY Assays for human growth hormone (HGH) were carried out on 89 acromegalic patients, 81 of whom were studied before any treatment had been given. Serial studies were undertaken, generally at 6-monthly intervals, with the same test procedure, using a 50 g oral glucose tolerance test (GTT) and identical assay conditions over a period of 8 years. Twenty-three patients were assessed at intervals during periods of up to 4 years whilst they remained untreated. The general picture was one of unchanging HGH levels. Ten patients were studied before and after external irradiation. HGH levels showed a slow continuing fall for as long as 4 years and thereafter they stabilized at one-third of pretreatment values. HGH levels in 12 patients treated with radioactive implants showed an immediate fall to one-third, and thereafter a further slow decline to one-tenth of pretreatment levels. The response in eight patients treated by surgical removal of pituitary tissue and subsequent radiotherapy varied considerably. No patient, treated or untreated, showed evidence of partial suppression of HGH secretion during the GTT although three patients consistently responded to glucose with paradoxical hypersecretion.


1979 ◽  
Vol 49 (2) ◽  
pp. 262-268 ◽  
Author(s):  
RICHARD C. EASTMAN ◽  
MAXINE A. LESNIAK ◽  
JESSE ROTH ◽  
PIERRE DE MEYTS ◽  
PHILLIP GORDEN

1984 ◽  
Vol 103 (3) ◽  
pp. 311-315 ◽  
Author(s):  
P. E. C Sibley ◽  
M. E. Harper ◽  
W. B. Peeling ◽  
K. Griffiths

ABSTRACT The immunocytochemical detection of endogenous human GH and the binding of exogenously applied human GH in tumour tissue from patients with benign prostatic hyperplasia or prostatic carcinoma is reported. Monoclonal human GH antibody binding was exclusively to the connective tissue in both benign and carcinomatous specimens. Specificity control experiments indicated that the antibody could be absorbed with human GH but not with human prolactin. Preincubating the sections with human GH considerably altered the immunocytochemical staining, reducing the reaction product within the connective tissue in a concentration-dependent manner and revealing a binding site for GH within the cytoplasm of epithelial cells. J. Endocr. (1984) 103, 311–315


Sign in / Sign up

Export Citation Format

Share Document